Novartis (NYSE:NVS)‘s stock had its “neutral” rating reissued by analysts at JPMorgan Chase in a report released on Monday.
Several other analysts also recently issued reports on NVS. Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. UBS reissued a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Finally, Zacks Investment Research downgraded shares of Novartis from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $87.51.
NYSE:NVS opened at $80.20 on Monday. The firm has a market capitalization of $185,859.97, a PE ratio of 16.67, a P/E/G ratio of 1.80 and a beta of 0.74. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. Novartis has a twelve month low of $72.67 and a twelve month high of $94.19.
Novartis (NYSE:NVS) last released its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.04. The company had revenue of $12.92 billion during the quarter, compared to analyst estimates of $12.65 billion. Novartis had a net margin of 15.69% and a return on equity of 16.03%. Novartis’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 EPS. analysts forecast that Novartis will post 5.33 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. boosted its holdings in Novartis by 1.6% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,425 shares of the company’s stock worth $3,814,000 after acquiring an additional 716 shares during the last quarter. Capital Bank & Trust Co boosted its holdings in shares of Novartis by 5.5% in the 3rd quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock worth $11,865,000 after buying an additional 7,201 shares during the last quarter. Atlantic Trust Group LLC boosted its holdings in shares of Novartis by 54.2% in the 3rd quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after buying an additional 25,452 shares during the last quarter. Rothschild Investment Corp IL boosted its holdings in shares of Novartis by 26.9% in the 4th quarter. Rothschild Investment Corp IL now owns 26,200 shares of the company’s stock worth $2,200,000 after buying an additional 5,550 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC purchased a new position in shares of Novartis in the 3rd quarter worth about $1,245,000. 10.76% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/novartis-nvs-earns-neutral-rating-from-jpmorgan-chase.html.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.